Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03595228
Other study ID # BRACHY-CHOR-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 31, 2018
Est. completion date January 25, 2022

Study information

Verified date March 2023
Source Bavarian Nordic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity is needed to proceed to stage 2.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date January 25, 2022
Est. primary completion date December 10, 2021
Accepts healthy volunteers No
Gender All
Age group 12 Years to 99 Years
Eligibility Inclusion Criteria: - Patients must have histologically confirmed chordoma - Patients must have measurable disease by RECIST 1.1 - Patients must be scheduled to have radiation therapy to at least 1 target lesion. - Age =12 years - Patients must have normal organ and marrow function - Must have recovered completely from any reversible toxicity associated with recent therapy. - There should be a minimum of 2 weeks from any chemotherapy, small molecule/targeted therapy, immunotherapy and/or radiation prior to enrolment - Females of childbearing potential and male partners of Females of childbearing potential must agree to use effective birth control or abstinence from screening to after the last vaccination therapy Exclusion Criteria: - Concurrent treatment for cancer, with specific exceptions noted in the inclusion criteria - Chronic hepatitis B or C infection. - Any significant disease, that in the opinion of the investigator may impair the patient's tolerance of trial treatment. - Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding, or rendering of informed consent. - Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment. This requirement is due to the potential risks of exacerbating autoimmunity. - Concurrent use of systemic steroids, except for physiological doses of systemic steroid replacement or local steroid use. - Patients who are receiving any other investigational agents within 28 days before start of trial treatment. - History of allergic reactions attributed to compounds of similar chemical or biological composition to MVA-BN/FPV-Brachyury or other agents used in trial. History of allergic reactions to aminoglycoside antibiotic or egg products. - Serious or uncontrolled intercurrent illness, included but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with trial requirements. - Pregnant women are excluded from this trial due to the unknown effects of the BN-Brachyury on the fetus or infant. - HIV-positive patients are ineligible because of the potential for decreased immune response to the vaccine. - Significant cardiovascular disease, which includes but is not limited to New York Heart Association Heart Failure Class II or greater, myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BN-Brachyury plus radiation
MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.

Locations

Country Name City State
United States Massachusetts General Hospital, Cancer Center Boston Massachusetts
United States MD Anderson Cancer Center Houston Texas
United States Mayo Clinic, Florida Jacksonville Florida
United States Mayo Clinic, Arizona Phoenix Arizona
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Bavarian Nordic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants With Injection Site Reaction Adverse Events by Preferred Term Includes Adverse Events that have injection site reactions indicated as the Adverse Event High Level Terms All AEs that are presented during or following initiation of trial treatment or worsens in severity are collected through the last scheduled visit (approximately 30 days after the last dose of treatment). Data were collected up to 29 months.
Other Frequencies of Participants With Occurrence, Severity and Seriousness of Adverse Events Occurrence is defined as the number of participants who experienced an AE. Related SAEs are defined as those for which causality to trial vaccine was considered possible, probable, definite, or was missing. Intensity is defined per CTCAE v4.03 grade. All AEs that are presented during or following initiation of trial treatment or worsens in severity are collected through the last scheduled visit (approximately 30 days after the last dose of treatment). Data were collected up to 29 months.
Other Worst CTCAE Toxicity Grade Shift From Baseline in Laboratory Results (Hematology and Serum Chemistry) For hematology and chemistry laboratory parameters with CTCAE grading scales, toxicity grade shift is defined to evaluated categorical changes from baseline results to post-treatment results with respect to dichotomized CTCAE grading value (<= Grade 2, >= Grade 3). Grade 0=No adverse event or within normal limits; Grade 1=Mild adverse event; Grade 2=Moderate adverse event; Grade 3=Severe and undesirable adverse event; Grade 4=Life-threatening or disabling adverse event; Grade 5=Death related to adverse event. Higher scores mean worse outcome. Overall Treatment Period: The time from the day of first treatment to the last scheduled trial visit, approximately 30 days after the last treatment visit. Data were collected up to 29 months.
Primary Objective Response Rate (ORR) Rate of subjects achieving a best response of either Complete Response or Partial Response per modified RECIST v1.1. A modified RECIST v1.1 assessment is based on targeted radiated lesion(s). Progression of a non-target lesion does not result in disease progression by the modified RECIST evaluation for this trial. Assessment for targeted radiated lesion(s): Complete Response (CR)=Disappearance of all target radiated lesions; Partial Response (PR)= >=30% decrease in the sum of the longest diameter of target radiated lesions; Progressive Disease (PD) = >=20% increase in the sum of the longest diameter of target radiated lesions, Stable Disease (SD)=-30% Within 12 months post-completion of radiation on target lesion(s) based on modified RECIST v1.1
Secondary Progression-free Survival (PFS) Kaplan-Meier of the time interval from first treatment to objective tumor progression based on modified RECIST v1.1 or death. A modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) based on targeted radiated lesion(s) will be used. Progression will be defined as a 20% increase in the sum of the longest diameter of target radiated lesions in this trial, and a progression of a non-target lesion does not result in disease progression by the modified RECIST evaluation used for this trial. Time from the day of first treatment to the start of disease progression or death, whichever occurs first up to 30 days after last tumor assessment visit. Data were collected up to 29 months.
Secondary Baseline and Overall Treatment Period Change From Baseline Brief Pain Improvement-Short Form Best Observed Scores Pain intensity and pain interference scores are summarized. Pain intensity scores includes pain items "Worst Pain in the Last Week", "Least Pain in the Last Week", and "Average Pain in the Last Week" and "Pain Right Now". Composite pain severity score (a mean severity score of the four pain items listed before). Composite pain interference score (a mean of the seven interference items). This will be calculated if at least four of the seven interference items have been completed on a given administration. Pain scores range from 0 to 10 with a score of 10 is the worst pain imaginable and a score of 0 is no pain. Best observed scores is the lowest score value observed. Overall Treatment Period: The time from the day of first treatment to the last scheduled trial visit, approximately 30 days after the last treatment visit. Data were collected up to 29 months.
Secondary Baseline and Overall Treatment Period Change From Baseline Brief Pain Improvement-Short Form Worst Observed Scores Pain intensity and pain interference scores are summarized. Pain intensity scores includes pain items "Worst Pain in the Last Week", "Least Pain in the Last Week", and "Average Pain in the Last Week" and "Pain Right Now". Composite pain severity score (a mean severity score of the four pain items listed before). Composite pain interference score (a mean of the seven interference items). This will be calculated if at least four of the seven interference items have been completed on a given administration. Pain scores range from 0 to 10 with a score of 10 is the worst pain imaginable and a score of 0 is no pain. Worst observed scores is the highest score value observed. Overall Treatment Period: The time from the day of first treatment to the last scheduled trial visit, approximately 30 days after the last treatment visit. Data were collected up to 29 months.
See also
  Status Clinical Trial Phase
Completed NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT06140732 - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT02383498 - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Phase 2
Recruiting NCT03242382 - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Recruiting NCT02986516 - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease N/A
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Phase 1
Active, not recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2
Completed NCT00713037 - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas N/A